MAXWELL FINLAND, F.A.C.P.; WILLIAM C. SPRING JR.; FRANCIS C. LOWELL; JOHN W. BROWN
This content is PDF only. Please click on the PDF icon to access.
Advances in the therapy of pneumonia have been occurring in recent years at an ever-accelerating pace. Nearly three decades elapsed from the earliest recognition of the etiological relationship of the pneumococcus to pneumonia in man and its first successful therapeutic application in specific serum treatment. This first step in the specific therapy of pneumonia was made possible through the subdivision of pneumococci into specific types. Therapy then became available for the most common of these types, namely, Type I. From the earliest use of specific antipneumococcus horse serums in the treatment of pneumococcus Type I pneumonia, it was recognized that,
FINLAND M, SPRING WC, LOWELL FC, et al. SPECIFIC SEROTHERAPY AND CHEMOTHERAPY OF THE PNEUMOCOCCUS PNEUMONIAS*. Ann Intern Med. 1939;12:1816–1829. doi: https://doi.org/10.7326/0003-4819-12-11-1816
Download citation file:
Published: Ann Intern Med. 1939;12(11):1816-1829.
Infectious Disease, Pneumonia, Pulmonary/Critical Care, Streptococcal Infections.
Results provided by:
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use